Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 12

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 12
---
Plan of Distribution.” |

| Use of proceeds | We will not receive any proceeds from the sale of shares being sold by the selling stockholders. We will, however, receive proceeds on the exercise by the selling stockholders of outstanding warrants for shares of our common stock covered by this prospectus if the warrants are exercised for cash. See “Use of Proceeds.” |

| Nasdaq Capital Market Symbol | “HURA”. |

| Risk factors | Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 5 of this prospectus for a discussion of factors you should carefully consider before investing in our common stock. |

The number of shares of common stock to be outstanding after the Offering is based on 51,103,535 shares of common stock outstanding at September 11, 2025 (assuming exercise by the selling stockholders of all warrants being offering), excludes the following as of September 11, 2025:

| • |     | 6,488,116 shares of common stock issuable upon the exercise of stock options outstanding at a weighted exercise price of $5.13 per share; |

| • |     | 9,328,113 shares of common stock reserved for future issuance under our TuHURA Biosciences, Inc. 2024 Equity Incentive Plan; |

| • |     | 13,197,640 shares of common stock issuable upon the exercise of warrants outstanding at a weighted exercise price of $4.58 per share; |

| • |     | up to 1,539,958 shares of common stock reserved for issuance that may be issued pursuant to the terms of the Contingent Value Rights Agreement, dated as of October 18, 2024, between the Company (f/k/a Kintara Biosciences, Inc.) and Equiniti Trust Company, LLC; and |

| • |     | up to 1,129,885 shares reserved for issuance as delayed merger consideration to the Kineta stockholders, subject to adjustment for certain losses incurred or accrued during the six-month period following the closing of the Kineta Merger. |

4

RISK FACTORS SUMMARY OF RISK FACTORS The following is a summary of the principal risks and uncertainties that could materially adversely affect our business, results of operations, financial condition, cash flows, prospects and/or the price of our outstanding securities and make an investment in our securities speculative or risky. You should read this summary together with the more detailed description of each